

Webcast: Life Sciences 2025 Outlook

Webcast Series: Capital Markets

Webcasts | March 19, 2025

The life sciences industry entered 2025 with a largely favorable set of catalysts, but also with some larger risks that will impact companies differently. Join our team of seasoned attorneys and industry leaders for part two of this webcast series, where we provide an integrated outlook on capital markets in the life sciences, identifying trends and uncertainties that will shape the year ahead. [Click here](#) to view the video recording and program materials from part one of this series on royalty finance in the life sciences, and read the full Life Sciences 2025 Outlook [here](#). Topics include:

- Key development in 2024: a modest increase in capital markets activity in 2024, including a nearly 55% increase in initial public offerings (off a low base level to start), which is also expected to continue to gain momentum in 2025
- Expected impacts of a shifting geopolitical environment and regulatory landscape under the Trump administration

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

MCLE CREDIT INFORMATION: This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 0.75 credit hours, of which 0.75 credit hours may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit. Attorneys seeking New York credit must obtain an Affirmation Form prior to watching the archived version of this webcast. Please contact CLE@gibsondunn.com to request the MCLE form. Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 0.75 hours in the General Category. California attorneys may claim "self-study" credit for viewing the archived version of this webcast. No certificate of attendance is required for California "self-study" credit.

PANELISTS:

- Ryan Murr (Gibson Dunn)
- Branden Berns (Gibson Dunn)
- Melanie Neary (Gibson Dunn)
- Bud O'Hara (Jefferies)

© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.

Related Capabilities

[Life Sciences](#)